Rockwell Medical Inc  

(Public, NASDAQ:RMTI)   Watch this stock  
Find more results for Robert J. Bagley�
10.51
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 8.10 - 12.47
Open     -
Vol / Avg. 0.00/500,017.00
Mkt cap 528.33M
P/E     -
Div/yield     -
EPS -0.39
Shares 50.27M
Beta 1.17
Inst. own 27%
Jul 29, 2015
Q2 2015 Rockwell Medical Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 21, 2015
Rockwell Medical Inc Annual Shareholders Meeting
May 13, 2015
Rockwell Medical Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Q1 2015 Rockwell Medical Inc Earnings Call - Webcast
May 7, 2015
Q1 2015 Rockwell Medical Inc Earnings Release
Feb 26, 2015
Q4 2014 Rockwell Medical Inc Earnings Call - Webcast
Feb 26, 2015
Q4 2014 Rockwell Medical Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -26.64% -39.36%
Operating margin -27.46% -32.40%
EBITD margin - -30.57%
Return on average assets -15.21% -31.75%
Return on average equity -21.74% -61.55%
Employees 283 -
CDP Score - -

Address

30142 S Wixom Rd
WIXOM, MI 48393-3440
United States - Map
+1-248-9609009 (Phone)
+1-248-9609119 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rockwell Medical, Inc. is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis (also referred to as dialysis). The Company’s investigational drug, Triferic, also known as Soluble Ferric Pyrophosphate or SFP, delivers iron to the bone marrow in a non-invasive, physiologic manner to hemodialysis patients via dialysate during the regular dialysis treatment. Triferic will substantially improve iron therapy for these patients. The Company successfully completed the two pivotal studies, CRUISE-1 and CRUISE-2, in Triferic's Phase 3 clinical program during fiscal 2013. The Company prepares to launch a generic drug called Calcitriol. Calcitriol is active vitamin D injection and indicated for the treatment of secondary hyperparathyroidism in dialysis patients.

Officers and directors

Robert L. Chioini Chairman of the Board, President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Thomas E. Klema CPA, MBA Chief Financial Officer, Vice President, Treasurer, Secretary
Age: 61
Bio & Compensation  - Reuters
Ajay Gupta M.D. Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Raymond D. Pratt M.D. Chief Medical Officer
Age: 64
Bio & Compensation  - Reuters
Patrick J. Bagley Independent Director
Age: 50
Bio & Compensation  - Reuters
Ronald D. Boyd Independent Director
Age: 52
Bio & Compensation  - Reuters
Kenneth L. Holt Independent Director
Age: 62
Bio & Compensation  - Reuters